At 47.6x trailing earnings but only 5.6x forward earnings, the market is pricing in a dramatic earnings normalization, yet the balance sheet tells a far more fragile story. An Altman Z-Score of 1.1 signals elevated financial distress risk, and a razor-thin 2.40% operating margin combined with 1.80% ROIC suggests the core business barely clears its cost of capital. The 0.3 Price/Sales and 1.1 Price/Book ratios imply deep value optics, but a 4.60% ROE and 0.5 current ratio show limited profitability and weak liquidity. This is not a clean mispricing; it is a leveraged cyclical trading at a distressed multiple because the market questions durability, not because it has missed a high-quality compounder.